Loading…
Jubilant Ingrevia (JUBLINGREA)₹587.65−0.29%Specialty Chemicals
In the Sep 2026 quarter (consolidated), Jubilant Ingrevia reported sales of ₹1,393 Cr, up 24.2% from Sep 2025, and net profit of ₹111 Cr, up 60.7% year on year. For the year to Mar 2026, sales were ₹4,388 Cr and net profit ₹277 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 966 | 1,073 | 1,024 | 1,045 | 1,058 | 1,051 | 1,039 | 1,121 | 1,051 | 1,179 | 1,300 | 1,393 |
| Expenses | 874 | 987 | 918 | 924 | 921 | 908 | 900 | 989 | 927 | 1,020 | 1,105 | 1,186 |
| Operating Profit | 95.76 | 90.81 | 110 | 124 | 138 | 147 | 142 | 135 | 126 | 163 | 199 | 211 |
| OPM % | 10.1% | 8.0% | 11.1% | 12.1% | 13.1% | 14.1% | 14.0% | 12.1% | 12.1% | 14.0% | 15.0% | 15.1% |
| Other Income | 8.99 | 9.99 | 9.99 | 9.98 | 8.98 | 7.98 | 10.98 | 10.98 | −3.99 | 8.99 | 9.98 | 8.99 |
| Interest | 15.03 | 14.02 | 14.02 | 15.03 | 12.02 | 14.02 | 13.01 | 12.02 | 12.03 | 12.02 | 17.04 | 22.04 |
| Depreciation | 34.11 | 36.09 | 39.09 | 40.11 | 40.07 | 39.08 | 41.10 | 41.11 | 45.12 | 48.15 | 51.15 | 51.16 |
| Profit before tax | 54.94 | 50.94 | 65.94 | 79.93 | 95.95 | 102 | 100 | 92.97 | 64.92 | 112 | 141 | 148 |
| Tax % | 30.1% | 43.1% | 26.1% | 26.1% | 27.1% | 27.1% | 25.1% | 25.1% | 28.1% | 23.1% | 25.1% | 25.1% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −8.96 | 0.00 | 0.00 | 0.00 |
| Net Profit | 38.87 | 28.89 | 48.85 | 58.84 | 68.74 | 73.79 | 74.74 | 68.82 | 46.88 | 85.68 | 106 | 111 |
| EPS (Rs) | 2.41 | 1.83 | 3.05 | 3.69 | 4.34 | 4.63 | 4.70 | 4.35 | 2.93 | 5.42 | 6.62 | 6.98 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 684 | 4,951 | 4,772 | 4,133 | 4,177 | 4,388 | 4,922 |
| Expenses | 0.00 | 569 | 4,122 | 4,241 | 3,722 | 3,672 | 3,834 | 4,238 |
| Operating Profit | 0.00 | 117 | 839 | 547 | 426 | 518 | 567 | 698 |
| OPM % | — | 17.0% | 17.0% | 11.0% | 10.0% | 12.1% | 13.0% | 14.2% |
| Other Income | 0.00 | −9.99 | 21.98 | 31.96 | 28.96 | 37.91 | 26.96 | 23.97 |
| Interest | 0.00 | 7.01 | 31.03 | 22.04 | 53.09 | 56.07 | 49.08 | 63.13 |
| Depreciation | 0.00 | 22.04 | 123 | 122 | 136 | 158 | 176 | 196 |
| Profit before tax | 0.00 | 76.98 | 709 | 437 | 268 | 344 | 370 | 466 |
| Tax % | 0.0% | 30.1% | 33.1% | 30.1% | 32.1% | 27.1% | 25.1% | — |
| Exceptional items | 0.00 | −8.96 | −5.97 | −0.99 | −3.98 | 0.00 | −9.97 | −8.96 |
| Net Profit | 0.00 | 53.87 | 475 | 307 | 182 | 250 | 277 | 349 |
| EPS (Rs) | −3.39 | 3.40 | 29.86 | 19.26 | 11.46 | 15.71 | 17.41 | 21.95 |
| Dividend payout % | 0.0% | 9.9% | 16.9% | 26.0% | 42.9% | 31.0% | 28.0% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 16.02 | 16.01 | 16.01 | 16.02 | 16.01 | 16.03 |
| Reserves | 0.00 | 1,908 | 2,419 | 2,654 | 2,725 | 2,915 | 3,112 |
| Borrowings | 0.00 | 556 | 238 | 407 | 740 | 764 | 792 |
| Other Liabilities | 0.00 | 884 | 1,106 | 1,170 | 1,235 | 1,318 | 1,544 |
| Total Liabilities | 0.00 | 3,363 | 3,779 | 4,247 | 4,716 | 5,013 | 5,465 |
| Fixed Assets | 0.00 | 1,802 | 1,795 | 1,844 | 2,536 | 2,579 | 3,178 |
| CWIP | 0.00 | 65.17 | 174 | 526 | 332 | 526 | 154 |
| Investments | 0.00 | 49.88 | 5.99 | 7.99 | 14.98 | 36.95 | 32.97 |
| Other Assets | 0.00 | 1,446 | 1,803 | 1,869 | 1,833 | 1,871 | 2,098 |
| Inventories | 0.00 | 609 | 911 | 1,035 | 940 | 942 | 879 |
| Trade receivables | 0.00 | 470 | 580 | 510 | 571 | 607 | 782 |
| Cash & equivalents | 0.00 | 117 | 48.95 | 84.93 | 79.85 | 98.81 | 190 |
| Total Assets | 0.00 | 3,363 | 3,779 | 4,247 | 4,716 | 5,013 | 5,465 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from operating activity | 112 | 453 | 463 | 431 | 508 | 524 |
| Cash from investing activity | 32.89 | −70.75 | −467 | −566 | −388 | −249 |
| Cash from financing activity | −72.06 | −419 | 42.05 | 144 | −129 | −155 |
| Net cash flow | 73.22 | −36.12 | 35.13 | 6.02 | −9.03 | 119 |
| Capex | 27.98 | 230 | 481 | 568 | 366 | 299 |
| Free cash flow | 85.34 | 226 | −16.06 | −136 | 157 | 236 |
| CFO / OP % | 106.0% | 69.0% | 98.0% | 111.0% | 113.0% | 111.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor days | 251 | 43 | 39 | 50 | 53 | 65 |
| Inventory days | 602 | 118 | 147 | 161 | 164 | 141 |
| Days payable | 686 | 104 | 114 | 132 | 142 | 151 |
| Cash conversion cycle | 168 | 58 | 73 | 81 | 76 | 56 |
| Working capital days | 221 | 50 | 43 | 38 | 30 | 23 |
| ROCE % | 8.0% | 29.0% | 16.0% | 10.0% | 11.0% | 11.0% |
For the Sep 2026 quarter, Jubilant Ingrevia reported sales of ₹1,393 Cr, up 24.2% year on year and net profit of ₹111 Cr, up 60.7% year on year. The operating margin was 15.1%.
Jubilant Ingrevia's sales for the year to Mar 2026 were ₹4,388 Cr; over the last twelve months they were ₹4,922 Cr.
Net profit for the year to Mar 2026 was ₹277 Cr, and ₹349 Cr over the last twelve months. Earnings per share over the same trailing period were ₹21.95.
Jubilant Ingrevia reported borrowings of ₹792 Cr at Mar 2026, against cash and equivalents of ₹190 Cr.
Cash from operations was ₹524 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹236 Cr.